Skin cancer is the fastest growing cancer in the world. Experts predict the number of people diagnosed with non-melanoma skin cancer will grow to nearly six million by the year 2020. With the epidemic of basal and squamous cell skin cancer diagnosis follows the common and less than ideal solution of surgical non-melanoma skin cancer treatment.

If you have been diagnosed with non-melanoma skin cancer including basal or squamous cell carcinoma, it’s time for you to discover the non-surgical benefits you deserve, with the SRT-100™. SRT stands for Superficial Radiotherapy, which consists of a precise, calibrated dose of Superficial Radiotherapy that only goes skin deep, safely destroying the skin cancer without causing any collateral damage to healthy skin cells.

This makes the SRT-100™ an ideal choice if you suffer from medical conditions that can make surgical non-melanoma skin cancer treatment a serious health risk, such as diabetes or cardiac disease. There is no need for anesthesia, no risk of infection or scarring, and no need for reconstructive plastic surgery.

The SRT-100™ is especially well suited for skin cancers located where nearly 80 percent of all skin cancer occurs, the head and neck. Since the SRT-100™ delivers such a controlled and precise dose of Superficial Radiotherapy, it can delicately reach areas that are difficult to treat such as the nose, lining of the ear, lips, eyelids, and corner of the mouth.

This non-invasive alternative to surgical treatment has proved to be remarkably safe and effective for over 50 years. Even without the cutting, pain, downtown or scarring, the SRT-100™ non-melanoma skin cancer treatment delivers a 95 percent plus cure rate for non-melanoma skin cancer.

Do you or a loved one suffer from non-melanoma skin cancer? Ask your doctor about the revolutionary SRT-100™ for non-melanoma skin cancer treatment or contact Sensus Healthcare today for more information.